134 related articles for article (PubMed ID: 8142163)
1. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group.
Guastalla JP; Vermorken JB; Wils JA; George M; Scotto V; Nooij M; ten Bokkel Huinnink WW; Dalesio O; Renard J
Eur J Cancer; 1994; 30A(1):45-9. PubMed ID: 8142163
[TBL] [Abstract][Full Text] [Related]
2. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB
Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389
[TBL] [Abstract][Full Text] [Related]
3. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
Willemse PH; Sleijfer DT; de Vries EG; Boonstra H; Bouma J; Mulder NH
Eur J Cancer; 1992; 28(2-3):479-81. PubMed ID: 1591067
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer.
Guastalla JP; Lhomme C; Kerbrat P; Mayer F; Namer M; Goupil P; Charrot P; Heron JF; Chazard M; Richard I
Ann Oncol; 1994 Feb; 5(2):127-32. PubMed ID: 8186155
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer.
de Jong RS; Willemse PH; Boonstra H; de Vries EG; van der Graaf WT; Sleijfer DT; van der Zee AG; Mulder NH
Eur J Cancer; 1995; 31A(5):709-13. PubMed ID: 7640042
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
10. Experimental and clinical results with intraperitoneal cisplatin.
ten Bokkel Huinink WW; Dubbelman R; Aartsen E; Franklin H; McVie JG
Semin Oncol; 1985 Sep; 12(3 Suppl 4):43-6. PubMed ID: 4048975
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
Kirmani S; Lucas WE; Kim S; Goel R; McVey L; Morris J; Howell SB
J Clin Oncol; 1991 Apr; 9(4):649-57. PubMed ID: 2066761
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy.
Reichman B; Markman M; Hakes T; Budnick A; Rubin S; Jones W; Almadrones L; Lewis JL; Hoskins W
Gynecol Oncol; 1991 Nov; 43(2):159-63. PubMed ID: 1743559
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
Berek JS; Markman M; Blessing JA; Kucera PR; Nelson BE; Anderson B; Hanjani P
Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H
Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
[TBL] [Abstract][Full Text] [Related]
16. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
17. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
